Edition:
India

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

1.20USD
15 Nov 2018
Change (% chg)

-- (--)
Prev Close
$1.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
36,256
52-wk High
$5.92
52-wk Low
$1.02

Latest Key Developments (Source: Significant Developments)

Collidion Announces Settlement Of Sonoma Litigation
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Sonoma Pharmaceuticals Inc ::COLLIDION ANNOUNCES SETTLEMENT OF SONOMA LITIGATION.SONOMA PHARMACEUTICALS INC - TERMS OF SETTLEMENT ARE OTHERWISE BEING KEPT CONFIDENTIAL.  Full Article

Montreux Equity Partners V Reports 8.8 Pct Stake In Sonoma Pharmaceuticals As Of Nov 2, 2018
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - Montreux Equity Partners V::MONTREUX EQUITY PARTNERS V, L.P. REPORTS 8.8% STAKE IN SONOMA PHARMACEUTICALS INC AS OF NOVEMBER 2, 2018 - SEC FILING.MONTREUX EQUITY PARTNERS V - NOW HAVE INTENT TO INFLUENCE POLICIES OF SONOMA PHARMACEUTICALS INC.MONTREUX EQUITY PARTNERS V - PROPOSE SHARON BARBARI, JAY BIRNBAUM, JERRY MCLAUGHLIN RESIGN FROM SONOMA BOARD .MONTREUX EQUITY PARTNERS V - ON NOVEMBER 2, 2018, DANIEL TURNER ON BEHALF OF MEP V, SENT LETTER TO BOARD OF SONOMA PHARMACEUTICALS.MONTREUX EQUITY PARTNERS V - PROPOSED THAT SONOMA PHARMACEUTICALS SHOULD IMMEDIATELY REDUCE BOARD COMPENSATION.MONTREUX EQUITY PARTNERS V - PROPOSED THAT SONOMA PHARMACEUTICALS SHOULD PURSUE APPROPRIATE STRATEGIC ALTERNATIVES, INCLUDING SALE.MONTREUX EQUITY PARTNERS V - PROPOSED SONOMA PHARMACEUTICALS SHOULD IMMEDIATELY ELIMINATE TAKEOVER DEFENSES, INCLUDING POISON PILL RIGHTS PLAN.  Full Article

Sonoma Pharma Announces Licensing Of Antimicrobial Hypochlorous Acid Solution For Management Of Blepharitis In The Spanish/Portuguese Markets
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES LICENSING OF ANTIMICROBIAL HYPOCHLOROUS ACID SOLUTION FOR MANAGEMENT OF BLEPHARITIS IN THE SPANISH/PORTUGUESE MARKETS TO BRILL PHARMA, S.L..SONOMA PHARMACEUTICALS - OCUDOX IS EXPECTED TO BECOME AVAILABLE IN SPAIN AND PORTUGAL BEGINNING EARLY 2019.  Full Article

Sonoma Pharmaceuticals Inc - QTRLY Loss Per Share $0.55
Thursday, 9 Aug 2018 

Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS REPORTS FIRST QUARTER FY 2019 FINANCIAL RESULTS.Q1 REVENUE ROSE 14 PERCENT TO $4.4 MILLION.QTRLY LOSS PER SHARE $0.55.  Full Article

Sonoma Pharma Enters Into Deal For Distribution Of Dermatology Products Into Brazil
Tuesday, 5 Jun 2018 

June 5 (Reuters) - Sonoma Pharmaceuticals Inc ::U.SK, DERMATOLOGY ARM OF BRAZILIAN NC GROUP, AND SONOMA PHARMACEUTICALS ENTER INTO LICENSE AGREEMENT FOR EXCLUSIVE RIGHTS TO SONOMA’S DERMATOLOGY PRODUCTS IN BRAZIL.SONOMA PHARMACEUTICALS - ENTERED INTO DEAL FOR EXCLUSIVE DISTRIBUTION OF MULTIPLE SONOMA DERMATOLOGY PRODUCTS INTO BRAZIL.SONOMA PHARMACEUTICALS INC - FIRST PRODUCTS ARE EXPECTED TO HIT MARKET IN AUGUST 2018.  Full Article

Sonoma Pharma Gets Three New UAE Regulatory Approvals
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS.SONOMA PHARMACEUTICALS INC - ANTICIPATE LAUNCHING ALL THREE PRODUCTS ACROSS UNITED ARAB EMIRATES IN FEBRUARY 2018.  Full Article

Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS.  Full Article

Sonoma Pharmaceuticals announces FDA approval of expanded indication for Alevicyn
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Sonoma Pharmaceuticals Inc ::Announces FDA approval of expanded indication for Alevicyn to add antimicrobial language.Approved Alevicyn dermal spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms​.  Full Article

Sonoma Pharmaceuticals posts Q2 loss $‍0.67/shr from continuing operations​
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals reports robust top line growth for second quarter FY 2018 with 61 pct product revenue growth and total revenue of $4.3 million.Q2 revenue $4.3 million versus $2.8 million.Sonoma Pharmaceuticals qtrly loss per share from continuing operations​ $‍0.67.  Full Article

Sonoma Pharmaceuticals receives Brazilian approvals
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals receives Brazilian approvals to market multiple hypochlorous acid-based dermatology products.Sonoma Pharmaceuticals Inc - ‍is currently seeking to partner with a Brazilian healthcare co relative to licensing newly approved products.Sonoma Pharmaceuticals Inc - ‍issuance of regulatory approvals by Brazilian Ministério Da Saúde for 7 of co's dermatology products​.  Full Article